Glaukos Announces Participation in Piper Jaffray Healthcare Conference

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016, at 12:00 p.m. EST in New York City.

A live audio webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com and will be archived for 90 days.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161116006500/en/

Glaukos Corporation
Sheree Aronson
VP, Investor Relations
(949) 367-9600 ext 371
[email protected]

Source: Glaukos Corporation

You May Also Be Interested In

• Zum Begins Historic Electric School Bus Rollout in San Francisco
• The Villa Roma Resort Launches New Corporate Retreat Packages
• SMArtX Advisory Solutions Releases Q3 2026 Select List